Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Aug;80(8):1749-1758.
doi: 10.1161/HYPERTENSIONAHA.123.21132. Epub 2023 Jun 8.

Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial

Affiliations
Randomized Controlled Trial

Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial

Jordan B King et al. Hypertension. 2023 Aug.

Abstract

Background: Single-pill combination (SPC) antihypertensive products improve blood pressure control and medication adherence among patients with hypertension. It is unknown to what degree commercially available SPC products could be used to target an intensive systolic blood pressure goal of <120 mm Hg.

Methods: This cross-sectional analysis included participants randomized to the intensive treatment arm (goal systolic blood pressure <120 mm Hg) of the Systolic Blood Pressure Intervention Trial (SPRINT) using ≥2 antihypertensive medication classes at the 12-month postrandomization visit. Antihypertensive medication data were collected using pill bottle review by research coordinators, and regimens were categorized by the unique combinations of antihypertensive classes. We calculated the proportion of regimens used, which are commercially available as one of the 7 SPC class combinations in the United States as of January 2023.

Results: Among the 3833 SPRINT intensive arm participants included (median age, 67.0 years; 35.5% female), participants were using 219 unique antihypertensive regimens. The 7 regimens for which there are class-equivalent SPC products were used by 40.3% of participants. Only 3.2% of all medication class regimens used are available as a class-equivalent SPC product (7/219). There are no SPC products available with 4 or more medication classes, which were used by 1060 participants (27.7%).

Conclusions: Most SPRINT participants in the intensive arm used an antihypertensive medication regimen, which is not commercially available as a class equivalent SPC product. To achieve the SPRINT results in real-world settings, maximize the potential benefit of SPCs, and reduce pill burden, improvements in the product landscape are needed.

Registration: URL: https://www.

Clinicaltrials: gov/ct2/show/NCT01206062; Unique identifier: NCT01206062.

Keywords: antihypertensive; cardiovascular diseases; drug combinations; goal; hypertension.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Derington has received research funding to her institution from Amarin not related to the current project. Dr Bress has received research support to his institution from Novartis, Amgen, and Amarin not related to the current project. Dr Cushman reports: co-investigator in a ReCOR medical study; research funds to institution from George Medicines. The other authors report no conflicts.

Figures

Figure 1.
Figure 1.. Flow Diagram for Inclusion and Exclusion
SPRINT: Systolic Blood Pressure Intervention Trial
Figure 2.
Figure 2.. Relative popularity of antihypertensive medication regimens and SPC product availability, by the number of medication classes in the regimen.
Tree-map of all antihypertensive medication regimens with at least 2 classes combined which were used by participants in the intensive group at the 12-month visit. Each box represents a unique combination of antihypertensive medication classes. Box sizes are proportional to the frequency of use, with larger boxes representing more popular regimens. Solid color boxes represent regimens which are commercially available as an SPC product; white colored boxes are not. Only regimens that were used by more than 0.5% of the population are labeled.

References

    1. Wright JT Jr., Williamson J, Whelton P, Snyder J, Sink K, Roccoo M, Reboussin D, Mahboob R, Oparil S, Lewis C, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. 2015;373:2103–16. - PMC - PubMed
    1. Cushman WC, Ringer RJ, Rodriguez CJ, Evans GW, Bates JT, Cutler JA, Hawfield A, Kitzman DW, Nasrallah IM, Oparil S, et al. Blood Pressure Intervention and Control in SPRINT. Hypertension. 2022;79:2071–2080. - PubMed
    1. Jr Wright JT. Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FHHH, Margolis KL, Papademetriou V, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. J Am Med Assoc. 2005;293:1595–1608. - PubMed
    1. Cushman WC, Ford CE, Einhorn PT, Wright JT Jr, Preston RA, Davis BR, Basile JN, Whelton PK, Weiss RJ, Bastien A, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008;10:751–760. - PMC - PubMed
    1. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018;15. - PMC - PubMed

Publication types

Substances

Associated data